Drug Approval | April 10, 2023
Virpax reports on progress of Envelta
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Abbas will closely partner with CBC's business teams to identify, assess, and pursue investment opportunities and strategic acquisitions
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
The business serves the healthcare and laboratory sectors on the west coast of the United States.
The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Subscribe To Our Newsletter & Stay Updated
